CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-therapeutic-selection-for-a-patient-with-newly-diagnosed-braf-v600e-mutated-metastatic-melanoma/24365/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More